Diagnosis: Hand-foot syndrome (palmar-plantar erythrodysesthesia) from capecitabine
A 54-year-old female undergoing chemotherapy with capecitabine presents with painful, symmetric erythema and hyperkeratosis on her palms and soles. Symptoms began three weeks after treatment initiation, significantly impacting her daily activities and quality of life.
A 54-year-old female with a history of breast cancer presented with a three-week history of painful, symmetric erythema and hyperkeratosis on her palms and soles. The lesions were associated with burning and discomfort, exacerbated by ambulation and manual tasks. Examination revealed:Symmetric erythema affecting the palms and solesHyperkeratosis with fissuring and desquamationEdema of the affected areasAbsence of vesicles or bullaeSkin tenderness upon palpation
The patient began capecitabine therapy three weeks prior for metastatic breast cancer. She reported a gradual onset of symptoms, initially mild but worsening to severe pain and discomfort. She has no significant past medical history and denies any family history of dermatologic conditions. There were no recent changes in her skin care products or exposure to irritants. Prior to this episode, she was on supportive care and had no history of skin reactions to chemotherapy.Onset: Symptoms began three weeks into capecitabine treatment.Triggers: No known triggers besides chemotherapy.Prior treatments: Supportive care without dermatologic interventions.Past medical history: Breast cancer, no significant dermatologic history.Family history: Unremarkable for skin disorders.
Acute / First-Line ManagementDiscontinue capecitabine if severe symptoms are present.Topical corticosteroids (e.g., clobetasol propionate 0.05% ointment) applied twice daily to affected areas.Consider oral analgesics such as acetaminophen or NSAIDs for pain management.Use emollients liberally to maintain skin hydration and barrier function.Workup and Diagnostic ConfirmationClinical diagnosis based on history and examination.Consider patch testing if there is suspicion of contact dermatitis.Review complete blood count and liver function tests to rule out systemic effects of chemotherapy.Long-Term ManagementMonitor for recurrence of symptoms with subsequent cycles of capecitabine.Implement preventive measures such as avoiding hot water exposure and wearing protective gloves during activities.Educate patients about potential skin reactions and the importance of early reporting.Consider dose adjustment or alternative therapies if symptoms persist or worsen.
Contact Dermatitis: Typically presents with localized, pruritic erythema and vesicles; history of exposure to irritants or allergens is crucial for diagnosis.Psoriasis: Characterized by well-defined plaques with silvery scales, often with a family history; not typically associated with chemotherapy.Dermatophyte Infection: May cause scaling and erythema, but usually with more localized findings and associated pruritus; KOH preparation can confirm.Acute Erythema Multiforme: Presents with target lesions and systemic symptoms; history of recent infections or medications is often noted.Palmar Plantar Keratoderma: Chronic condition leading to thickened skin on palms and soles, but not typically painful or related to chemotherapy.Drug-Induced Erythema: Various medications can cause similar symptoms; detailed medication history is essential.Systemic Lupus Erythematosus: Can cause photosensitivity and acral erythema; associated systemic symptoms would guide further workup.Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia): Key association with specific chemotherapeutic agents like capecitabine, characterized by painful erythema and desquamation on palms and soles.
High-Yield PearlsRecognition: Hand-foot syndrome is a common adverse effect of capecitabine and other chemotherapeutic agents, requiring prompt recognition and management.Symptoms: Patients typically present with painful erythema, hyperkeratosis, and potential desquamation on palms and soles.Management: Early intervention with topical corticosteroids and emollients can significantly alleviate symptoms and improve quality of life.Prevention: Educating patients on protective measures can help mitigate the severity of symptoms during treatment.Monitoring: Regular follow-up is essential to manage recurrences and adjust chemotherapy regimens as necessary.Early recognition and management of hand-foot syndrome can greatly improve patient comfort and adherence to chemotherapy.
Tags: hand-foot syndrome, capecitabine, drug reaction